Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07538882 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 20, 2026 (before its estimated May 13, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The precise treatment of primary hepatocellular carcinoma (HCC) highly depends on accurate disease staging (CNLC, TNM, BCLC) and scientific treatment decision-making, which necessitate the integration of both imaging and clinical baseline data. This study prospectively recruits HCC patients and clinical physicians across different hospital tiers to evaluate the clinical value of a self-developed artificial intelligence (AI) model in assisting multi-dimensional comprehensive assessment and treatment decision-making. Utilizing a Multi-Rater Multi-Case (MRMC) crossover balanced design, the study compares the accuracy of clinical evaluations performed by physicians under "unassisted (without AI)" versus "AI-assisted" conditions. A key focus is to explore whether AI can significantly enhance the comprehensive assessment capabilities of physicians in primary/secondary care hospitals, thereby prospectively reducing diagnostic and therapeutic heterogeneity across different institutional levels.
Trial Details
NCT Number NCT07538882
Lead Sponsor Beijing Tsinghua Chang Gung Hospital
Collaborators: Affiliated Hospital of Hebei University, Meng Chao Hepatobiliary Hospital of Fujian Medical University, Zhongnan Hospital, Xingtai People's Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, Xinan hospital of Army Medical University
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC)
Related terms Carcinoma, Hepatocellular
Enrollment 108 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov